These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29568358)

  • 1. Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.
    Nishii N; Tachinami H; Kondo Y; Xia Y; Kashima Y; Ohno T; Nagai S; Li L; Lau W; Harada H; Azuma M
    Oncotarget; 2018 Mar; 9(17):13301-13312. PubMed ID: 29568358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade.
    Tachinami H; Nishii N; Xia Y; Kashima Y; Ohno T; Nagai S; Li L; Lau W; Tomihara K; Noguchi M; Azuma M
    Oral Oncol; 2019 Apr; 91():21-28. PubMed ID: 30926058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral delivery of TransCon
    Zúñiga LA; Leßmann T; Uppal K; Bisek N; Hong E; Rasmussen CE; Karlsson JJ; Zettler J; Holten-Andersen L; Bang K; Thakar D; Lee YC; Martinez S; Sabharwal SS; Stark S; Faltinger F; Kracker O; Weisbrod S; Müller R; Voigt T; Bigott K; Tabrizifard M; Breinholt VM; Mirza AM; Rosen DB; Sprogøe K; Punnonen J
    Cancer Cell Int; 2022 Sep; 22(1):286. PubMed ID: 36123697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.
    Penaloza-MacMaster P; Provine NM; Blass E; Barouch DH
    J Immunol; 2015 Aug; 195(3):1054-63. PubMed ID: 26116499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
    Gibbons Johnson RM; Dong H
    Front Immunol; 2017; 8():961. PubMed ID: 28848559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization.
    Sun NY; Chen YL; Wu WY; Lin HW; Chiang YC; Chang CF; Tai YJ; Hsu HC; Chen CA; Sun WZ; Cheng WF
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31546897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
    Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
    Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers.
    Osawa Y; Kojika E; Nishikawa K; Kimura M; Osakaya S; Miyauchi H; Kanto T; Kawakami Y; Kimura K
    Oncotarget; 2019 Apr; 10(32):3013-3026. PubMed ID: 31105882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer.
    Fu D; Wu J; Lai J; Liu Y; Zhou L; Chen L; Zhang Q
    Am J Cancer Res; 2020; 10(2):473-490. PubMed ID: 32195021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies.
    Iwai T; Sugimoto M; Wakita D; Yorozu K; Kurasawa M; Yamamoto K
    Oncotarget; 2018 Jul; 9(59):31411-31421. PubMed ID: 30140379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.
    Jing W; Gershan JA; Weber J; Tlomak D; McOlash L; Sabatos-Peyton C; Johnson BD
    J Immunother Cancer; 2015; 3(1):2. PubMed ID: 25614821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
    Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
    Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.
    Bai J; Gao Z; Li X; Dong L; Han W; Nie J
    Oncotarget; 2017 Dec; 8(66):110693-110707. PubMed ID: 29299180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy.
    Cai J; Wang D; Zhang G; Guo X
    Onco Targets Ther; 2019; 12():8437-8445. PubMed ID: 31686860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Immunotherapy with Micellar Resiquimod-Polymer Conjugates Triggers a Robust Antitumor Response in a Breast Cancer Model.
    Kakwere H; Zhang H; Ingham ES; Nura-Raie M; Tumbale SK; Allen R; Tam SM; Wu B; Liu C; Kheirolomoom A; Fite BZ; Ilovitsh A; Lewis JS; Ferrara KW
    Adv Healthc Mater; 2021 May; 10(10):e2100008. PubMed ID: 33646600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
    Salmon H; Idoyaga J; Rahman A; Leboeuf M; Remark R; Jordan S; Casanova-Acebes M; Khudoynazarova M; Agudo J; Tung N; Chakarov S; Rivera C; Hogstad B; Bosenberg M; Hashimoto D; Gnjatic S; Bhardwaj N; Palucka AK; Brown BD; Brody J; Ginhoux F; Merad M
    Immunity; 2016 Apr; 44(4):924-38. PubMed ID: 27096321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
    Shi L; Chen L; Wu C; Zhu Y; Xu B; Zheng X; Sun M; Wen W; Dai X; Yang M; Lv Q; Lu B; Jiang J
    Clin Cancer Res; 2016 Mar; 22(5):1173-1184. PubMed ID: 26933175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.